The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects with Acute Myeloid Leukemia (AML) no longer experiences symptoms of the disease The primary objective of the study is to evaluiate whether maintenance therapy with oral azacitidine improves OS compared with placebo in subjects with AML, age ≥55 years, who have achieved first CR o...

• Country None
• organs None
• Specialty None

A study to evaluate the drug Mongersen (GED-0301) for the treatment of Crohn’s disease To evaluate the efficacy of GED-0301 compared with placebo on clinical activity at 12 Weeks, in subjects with active Crohn’s disease (CD).

• Country None
• organs None
• Specialty None

A multi center study to assess the safety and efficacy of nab-paclitaxel with CC-486, nab-paclitaxel with MEDI4736 and nab-paclitaxel alone as 2nd/3rd line treatment in subjects with advanced NSCLC To estimate the efficacy of nab-paclitaxel administered intravenously (IV) on Days 8 and 15 with epigenetic modifying therapy of CC-486 once daily (QD) on Days 1 to 14 every 21 days or nab-paclitaxel ...

• Country None
• organs None
• Specialty None

To determine the safety, clinical efficacy, and effect of azacitidine on the body,within the body and interactions within the body in children and young adults with newly diagnosed advanced Myelodysplastic Syndromes or Juvenile myelomonocyctic leukemia before transplantation of the bone marrow and blood. At the end of the study, the data will be compared to data from an older study of patients with the same diseases The primary objective is to assess the treatment effect on response rate (MDS: CR, PR, or marrow CR; JMML: either cCR or cPR) at Cycle 3 Day 28 and to compare against standard therapy using a matched-...

• Country None
• organs None
• Specialty None

A study using a new drug (GED-0301) to investigate if the new drug works and is safe in subjects suffering ulcerative colitis To explore the effect of GED-0301 on clinical activity, as measured by the MMS in subjects with active UC.

• Country None
• organs None
• Specialty None

A Phase 2 placebo-controlled study to compare the effectiveness and safety of two doses of apremilast (CC-10004) in subjects with active rheumatoid arthritis, who have not responded to methotrexate treatment The primary objective is to evaluate the efficacy of two doses of apremilast (20 mg BID and 30 mg BID) compared with placebo on the reduction of signs and symptoms of RA at 24 weeks of treatment

• Country None
• organs None
• Specialty None

A Phase 3 study of the safety and effectiveness of Apremilast versus placebo in patients with moderate to severe plaque psoriasis Studio di fase 3 per valutare l`efficacia e la sicurezza di Apremilast in pazienti affetti da psoriasi a placche moderata e grave Evaluate the clinical efficacy of apremilast 30 mg BID, compared with placebo, in subjects with moderate to severe plaque psoriasis Valutare l'efficacia clinica di apremilast 30 mg BID, rispett...

• Country None
• organs None
• Specialty None

A clinical trial to evaluate if apremilast is safe in children and adolescents with moderate to severe plaque psoriasis as well as assessing how apremilast is processed by the body, and to determine the appropriate dose for them The primary objective of the study is to select a pediatric dose of apremilast based on the safety, tolerability, and PK of apremilast in adolescents and children with moderate to severe plaque psoria...

• Country None
• organs None
• Specialty None

A phase 2, multicenter, open-label, single arm, two-stage study to evaluate the efficacy and safety of CC-4047 (Pomalidomide) in patients with advanced soft tissue sarcomas who have relapsed or are refractory to systemic anticancer therapy To evaluate the efficacy of CC-4047

• Country None
• organs None
• Specialty None

Clinical study for patients with breast cancer that has spread to other parts of the body and that does not respond to hormonal or anti-HER2 therapy ('triple negative disease'), comparing a chemotherapy treatment (carboplatin + gemcitabine) with an experimental treatment of nab-paclitaxel plus chemotherapy (carboplatin OR gemcitabine) - Phase 2: evaluate the benefit and risk profiles of the two nab-paclitaxel experimental arms and identify the nab-paclitaxel combination that will be used in the Phase 3. - Phase 3: compare the p...

• Country None
• organs None
• Specialty None